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ABSTRACT 
 
Lipids - including fatty acids (FAs), triglycerides (TGs), cholesterol and cholesterol esters 
(CEs) - are hydrophobic molecules involved in several important structural and mechanistic 
processes. Lipids are found in cellular membranes, give posture and stability to the cell, are 
actively participating in cellular signaling, and act as mediators in several important 
biological pathways. Lipids, transported between organs through lipoprotein particles, act 
as an important energy source. Lipids are either directly utilized in metabolic processes or, 
if in excess, stored in depots in the cell cytosol. However, imbalances in lipoprotein 
transport or cellular metabolism of the lipids may give rise to adverse cellular effects 
leading to metabolic disorders and cardiovascular disease (CVD). The main underlying 
causes for these imbalances are of dietary, environmental and genetic nature. The focus of 
this thesis is on the genetic causes of dyslipidemia and the roles of the proprotein 
convertase subtilisin/kexin type 9 (PCSK9), apolipoprotein (APO) E, transmembrane 6 
superfamily member 2 (TM6SF2) and patatin-like phospholipase domain-containing 
protein 3 (PNPLA3) proteins. 
PCSK9 is a circulating protein that influences plasma low-density lipoprotein cholesterol 
(LDL-C) concentration and susceptibility to cardiovascular disease. Circulating PCSK9 
levels show considerable inter-individual variation, but the factors responsible for this 
variability are largely unknown. We analyzed circulating PCSK9 levels in 4 cohorts of 
healthy, middle-aged Swedes and found that PCSK9 levels varied over ~50-fold range and 
showed a positive relationship with plasma LDL-C concentration. Mapping of the PCSK9 
locus revealed a common polymorphism, (rs2479415, minor allele frequency (MAF) 
43.9%), located ~6 kb upstream from PCSK9, which was independently associated with 
increased circulating PCSK9 levels. 
It is generally assumed that the APOE concentration, in addition to the APOE ε2/ε3/ε4 
genotype, influences plasma lipoprotein levels, but a functional genetic variant influencing 
the plasma APOE concentration has not been identified. In a genome-wide association 
(GWA) study, we observed that the APOE locus was the only genetic locus showing robust 
associations with the plasma APOE concentration. Fine-mapping of the APOE locus 
showed that rs769446 (-427T/C) in the APOE promoter is independently associated with 
the plasma APOE concentration. The minor allele of rs769446 is associated with increased 
APOE mRNA levels (p= 0.015) as analyzed in 199 human liver samples. Transient 
transfection studies and electrophoretic mobility shift assays in human hepatoma HepG2 
   
 cells corroborated the role of rs769446 in transcriptional regulation of APOE.  
TM6SF2, a gene with unknown function, encodes a protein of 351 amino acids with 7-10 
predicted transmembrane domains. It is located on chromosome 19-12, a locus associated 
to the plasma TG concentration and hepatic lipid content. Gene expression studies in 
human liver samples demonstrated that TM6SF2 was the putative causal gene for this 
association. Subcellular localization studies showed that TM6SF2 is localized in the 
endoplasmic reticulum (ER) and the ER-Golgi intermediate compartment of human liver 
cells. Functional studies evaluating the secretion of TG-rich lipoproteins (TRLs) and lipid 
droplet (LD) content in Huh7 and HepG2 cells showed that TM6SF2 inhibition was 
associated with reduced secretion of TRLs and increased cellular triglyceride concentration 
and LD content, whereas TM6SF2 overexpression lead to reduced liver cell steatosis. 
The PNPLA3 gene variant I148M is an important marker of human non-alcoholic fatty liver 
disease (NAFLD), but the physiological function of PNPLA3 in liver fat metabolism 
remains unclear. We therefore analyzed PNPLA mRNA levels in human and mouse tissues 
and evaluated the effect of small interfering RNA (siRNA) silencing of PNPLA3 on TG 
metabolism in human Huh7 and HepG2 hepatoma cells. Although PNPLA3 had the highest 
expression level of all PNPLA family members in 91 human liver samples, PNPLA3 
silencing in Huh7 and HepG2 cells was not associated with changes in TRL secretion, 
cellular triglyceride content and the rate of triglyceride synthesis. 
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1 INTRODUCTION 
 
Lipids are molecules with high structural diversity that are involved in many tightly 
controlled physiological processes. The lipid diversity within cells, organelles, organs and 
species is highly conserved and important throughout evolution.1 To maintain homeostasis, 
triglycerides (TGs) should comprise 20-25% of total energy intake, the ratio of 
polyunsaturated to saturated fatty acids (FAs) should exceed 1.0, and that total serum 
cholesterol levels should be below 5 mmol/L.2 However, since the agricultural and 
especially the industrial revolution, we have experienced a conflict between our current 
diet/environment and our ancient genome.3 The shift towards increased consumption of 
saturated FAs, salt and carbohydrates has disturbed lipid homeostasis and resulted in an 
unprecedented increase of people suffering and dying from metabolic and cardiovascular 
disease (CVD).  
The causes of dyslipidemia are not only dietary or environmental. In nature it has been 
shown that genetic predisposition plays a vital role in lipid homeostasis and in the 
susceptibility to metabolic disorders and CVD.4 Monogenic forms of dyslipidemia, such as 
familial hypercholesterolemia have long been known to be associated with CVD.5 These 
disorders are caused by a single mutation within a gene that raises total cholesterol levels 
over 7 mmol/L. In complex diseases, the interaction of several low-impact genetic variants 
together with effects of dietary and environmental factors give rise to disease. Defining the 
genetic contribution in multigenic lipidemia and its implications in disease is therefore 
much more difficult. However, technological developments in the field of genome 
sequencing and genotyping have provided new insights in our understanding of these 
genetic variations. Together with qualitative functional studies this has shed new light on 
the mechanisms of dyslipidemia and their implication in diseases. This thesis focuses on 
defining the physiological roles of four genes involved in lipid metabolism. 
 
1.1  LIPOPROTEIN METABOLISM 
 
Cholesterol ester (CE) and TG molecules are transported to different organs for energy 
usage and storage. However, due to their non-polar carbon tail they are not compatible to 
freely flow via the blood or lymphatic vessels. This transport is mediated through the 
packaging of CEs and TGs in polar lipoprotein particles. Lipoprotein particles are 
composed of a core of non-polar lipids and a surface of polar proteins and phopholipids. 
They are synthesized in the liver and the intestine. A family of surface proteins called 
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 apolipoproteins (APO) serves as signal proteins in lipid metabolism. The size and nature of 
these lipoproteins varies according to their core lipid density and the nature of their surface 
proteins. The different lipoproteins are in order of size from largest to smallest (Figure 1): 
chylomicrons (CM), very-low density lipoproteins (VLDL), intermediate-density 
lipoproteins (IDL), low-density lipoproteins (LDL) and high-density lipoproteins (HDL).6 
Once in circulation, these particles are highly dynamic. They undergo size and 
conformation changes through hydrolysis and transfer reactions of their core lipid 
components and of their apolipoproteins. Lipoproteins are catabolized in the liver, kidney 
and the peripheral tissue via receptor-mediated mechanisms.7 
 
 
Figure 1. Classification of lipoproteins based on floatation density.  
Obtained from JM Saland, H. Pediatric Nephrology 2007;22: 1095-1112. 
 
1.1.1  Exogenous lipoprotein metabolism 
Dietary lipids are digested in the gut into glycerol and long chain FAs by bile salts and 
pancreatic lipases. Enterocytes absorb the glycerol molecules and FAs to resynthesize TGs, 
which are then assembled, with the help of the lipid transfer protein, microsomal triglyceride 
transfer protein (MTTP), in the endoplasmic reticulum (ER) and packaged together with 
APOB48 and APOA4 into pre-CMs. In the Golgi, the CMs gain more TGs and CEs and also 
acquire additional apolipoproteins. 8-12 
 
1.1.2  Endogenous lipoprotein metabolism 
Apart from the uptake of lipids from the diet, the liver has the ability to synthesize its own 
TGs and CEs. The origins of the FAs used for TG synthesis are i) de novo FA synthesis from 
acetyl-CoA, a process known as lipogenesis ii) hydrolysis of the plasma lipoproteins cleared 
by the liver iii) uptake of circulating FAs derived from the hydrolysis of adipose tissue lipids. 
These TGs enter the cytosolic TG pool in the liver and are then mobilized together with CEs 
and APOB100 protein to assemble VLDL particles. In the ER lumen of the hepatocytes, 
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APOB100 is co-translationally lipidated by MTTP, giving rise to pre-VLDL. Once this 
particle is sufficiently lipidated, it is retained in the ER, continuing lipidation to give rise to 
VLDL2. The VLDL2 particles in the ER are either converted to larger VLDL1 in the Golgi 
through further addition of TGs or secreted as VLDL2 into the lumen and ultimately the 
blood. The mechanism by which the cells secrete VLDL1 or VLDL2 is not yet fully 
understood.8-12   
 
1.1.3  Lipolysis and uptake of lipoproteins and its remnants 
CM secreted into circulation acquire APOE, APOC2 and APOC3 from HDL. Lipoprotein 
Lipase (LPL), activated by APOC2, hydrolyzes the TGs of the CMs into FA, which diffuse 
through the capillaries into muscle or skeletal cells. The lipolysis of TG gives rise to smaller 
particles called CM remnants, which are removed from the circulation by the liver primarily 
through LDL-receptor (LDLR) and LDLR-like protein 1 (LRP-1) with APOE as ligand. 
Once in the circulation, VLDL acquires APOC2. TGs in the VLDLs, similar to that of CMs, 
are hydrolyzed by LPL on the luminal surface of the capillary endothelium in muscle and 
adipose tissue. As the TGs are released, the VLDL shrinks in size and forms IDL particles. 
IDL has two fates; it is either removed from the circulation by a process mediated by APOE 
or undergoes further lipolysis by LPL losing APOE, apoC and more FAs, alternatively 
yielding LDL. Plasma LDL clearance occurs primarily via LDLR-mediated endocytosis in 
the liver and peripheral cells, with APOB100 as a ligand. The affinity of this binding is less 
than the APOE/LDLR affinity, resulting in a long half-life of the cholesterol-rich LDL in the 
circulation.13-17 
 
1.1.4  HDL and reverse cholesterol transport 
HDLs are lipoprotein that traffic cholesterol. They are synthesized in the liver and the 
intestine, lipidated on the surfaces of these organs with the help of ATP-binding cassette 
transporter A1 (ABCA1). APOA1 and APOA2 are the main lipoproteins on the surface of 
HDL molecules. Newly synthesized HDL particles obtain APOE and APOCs in an exchange 
process between HDL and APOB containing particles. In addition, HDLs acquire cholesterol 
from other lipoproteins and organ tissues during their time in the circulation. Most notable of 
these tissues is the arterial wall, hence reducing the cholesterol deposit burden. The continued 
esterification of free cholesterol into CE by the enzyme lecithin-cholesterol acyltransferase 
(LCAT) renders the maturation of the HDL molecule. Eventually, HDL particles empty their 
cholesterol load in the liver with the help of scavenger receptors (SRs) by a process called the 
direct cholesterol-transport pathway. HDLs are also able to exchange their cholesterol 
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 molecules with TGs of VLDLs and CMs, a process facilitated by cholesteryl-ester transfer 
protein (CETP). The transport of these cholesterol particles by LDL to the liver is known as 
the indirect cholesterol transport pathway. These processes are modulated by several enzymes 
and cell membrane transporters that lipidate or de-lipidate HDL. According to this model, 
increased numbers of APOB containing VLDL or LDL result in the transfer of excess TGs to 
HDL in exchange for CE molecules, thereby depleting the HDL particle from cholesterol 
molecules.8-12, 17-18 
 
Figure 2. Schematic representation of lipoprotein metabolism 
 
1.2 INTRACELLULAR LIPID METABOLISM 
 
1.2.1 Lipid droplets 
Until a decade ago, lipid droplets (LDs) were considered to be inert depots of fat found in 
mammalian adipose tissues. It is now known that LDs are found in all mammalian cells. LDs 
are dynamic organelles involved in lipid metabolism and also participate in response to ER 
stress, protein glycosylation and pathogen infection.19-22 LDs are composed of a mass of 
neutral lipids, predominantly CEs and TGs, surrounded by a phospholipid monolayer. The 
lipid monolayer harbors different proteins that are involved in the regulation and metabolism 
of lipids.19, 23-25 LDs are localized in the cytosol of most cells, but their quantity and size 
varies across different cell-types. The two main cell-types that contain LDs are adipocytes 
and hepatocytes. Adipocytes contain one large LD in the cytoplasm (up to 100𝜇m in 
diameter) whereas hepatocytes contain a large number of LDs of relatively smaller size (2-
10𝜇m in diameter).  
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1.2.2  Proteins involved in LD metabolism 
Neutral lipids are formed from the transfer of FAs to lipid alcohols. Several ER membrane-
bound enzymes utilize FAs to catalyze this step. For example, diacylglycerol acyltransferase 
(DGAT) enzymes utilize FA and diacylglycerol (DG) to form TGs. Similarly; FA is 
condensed with cholesterol to produce CEs. The FA substrates for the neutral lipids are either 
supplied through i) lipogenesis, where acetyl-CoA acts as a precursor to a group of FA 
synthetases such as acetyl-CoA acetyltransferases (ACATs), glycerol 3-phosphate 
acyltransferases (GPATs) and Lipins or from ii) plasma uptake and esterification of free FAs 
after lipoprotein degradation and transferring them to form more complex neutral lipids with 
the help of monoacylglycerol O-acyltransferases (MOGATs) and DGATs.19  
 
1.2.3  LD formation 
The exact mechanism by which LDs are formed is unknown. A reason for this is the small 
size of the nascent LDs and the difficulties of available technologies to detect such small 
molecules in a time-lapse fashion. However, the general consensus for LD origins is the ER 
membrane. Three models for nascent LD biogenesis are proposed: (Figure 3) 
a) “Lensing model”: Neutral lipids are deposited between the ER-lumen and cytosolic 
leaflets of the ER membrane, producing a bulging on the cytosolic leaflet size, which 
dissociates into an LD particle once a certain size is reached. Membrane proteins are 
dissociated with the cytosolic leaflet composing the LD membrane. 
b) Bicelle formation: Neutral lipids are deposited in similar fashion as the “lensing 
model”, but both leaflets of the ER membrane constitute the LD membrane as they 
are excised from the ER once a certain size is reached. 
c) Vesicle formation: The leaflets are rearranged forming a vesicle, followed by active 
TG incorporation.23-28 
 
 
 
 
 
 
 
 
 
 
Figure 3. LD formation according to  
A) Lensing model, where the neutral lipid core bulges 
from the cytosolic membrane of the ER after reaching 
a critical size. 
B) Bicelle formation, neutral lipids fill the ER membrane 
and both membranes of the ER are excized to form the 
outer LD membrane. 
C) Vesicle formation through rearrangement of the 
innermost membrane and active TG incorporation to 
form the LD. 
 
Obtained from Van der Klei IJ. et. Al. Genetics. Jan;193(1):1-50. (2013). 
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 1.2.4  LD growth 
The mechanism for LD growth is not yet fully understood, but several mechanisms have been 
proposed. One proposed mechanism involves the synthesis of TGs at the surface of LDs. 
Surface phospholipids are removed from the LDs by the coatamer protein (COP) 1 
machinery, increasing surface tension of the LDs facilitating the interaction with the ER-
membrane, establishing an ER-LD membrane-bridge. This bridge facilitates the 
unidirectional relocation of TG synthesis enzymes from the ER to the LD to locally produce 
TGs, leading to the growth of the LD. Another proposed mechanism of LD growth is through 
permeation, where neutral lipids are actively transferred from a smaller to a larger LD. Fat 
specific protein 27 is an enzyme facilitating this transfer in adipocytes. A third proposed 
mechanism of LD growth is through fusion. Here, two LDs with different surface tensions 
interact and form one larger LD.29-33 
 
1.2.5  LD lipolysis 
Lipid homeostasis in organs is crucial to prevent diseases such as type 2 diabetes (T2D), non-
alcoholic fatty liver disease (NAFLD), obesity and various forms of lipodystrophy. FAs that 
are not directly oxidized for energy production are packaged as TGs in LDs for later use. 
How, when and at what rate TGs and CEs are hydrolyzed differs depending on the organ, cell 
type, milieu and nutritional need. LD-TGs are hydrolyzed in all cells through the activity of 
lipases recruited to the LD surface by LD surface proteins. The best known intracellular 
lipases are adipose triglyceride lipase (ATGL, now called PNPLA2), hormone-sensitive 
lipase (HSL) and monoacylglyceride lipase (MGLL). These enzymes act on TG (PNPLA2), 
(DG) (HSL) or MG (MGLL) to release FAs that are either used in energy production or 
incorporated with other lipid molecules. It was shown that LDs smaller in size are generally 
degraded faster than larger LDs. This is probably due to the higher lipolytic activity of lipases 
on smaller LD surfaces where these proteins have a denser surface-to-volume ratio. There are 
however conditions in which larger LDs are degraded quicker than smaller LDs. This is 
explained by conditions rendering differential localization of regulatory surface proteins, i.e. 
Perilipin1 (PLIN1). It was recently shown that PNPLA3, a protein with homology to 
PNPLA2, might also have intracellular lipolytic properties in liver and adipocytes. A mutated 
PNPLA3 (I148M) was observed to promote TG accumulation and hepatic steatosis.34-38  
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1.2.6  LD heterogeneity 
LDs are ubiquitously expressed dynamic organelles in the body. They are of different sizes 
and protein composition. These differences are thought to be the result of parallel actions of 
lipogenesis, growth, lipolysis and the unique composition and density of the surface proteins 
in each specific LD. The biological significance of this heterogeneity lies in maintaining the 
homeostasis of intracellular lipid levels by controlling the FA flow, but it is not clear how the 
size affects the metabolic fate of LDs.30-35 
 
1.3  PATHOPHYSIOLOGY OF DYSLIPIDEMIA IN CARDIOVASCULAR DISEASE 
 
1.3.1  Introduction 
CVD is the leading cause of death worldwide. An estimated of 17.3 million people died of 
CVD in 2008. In Sweden, 1.4 million people live with the disease and 40% of the total deaths 
are due to CVD. The estimated costs of CVD for the year 2013 exceeded 60 billion SEK. 
CVD comprises a group of disorders of the heart and the blood vessels. The most important 
of these disorders are: coronary heart disease (CHD), involving the blood vessels supplying 
the heart muscle; cerebrovascular disease (CVA), involving the blood vessels supplying the 
brain; peripheral arterial disease (PAD), involving the blood vessels supplying the arms and 
legs; deep vein thrombosis and pulmonary embolism, the consequence of blood clots in the 
leg veins, which can dislodge and move to the heart and lungs.39-40 
 
1.3.2  CVD and risk factors 
CVD is associated to several risk factors. These include a history of CVD, male gender, age, 
ethnicity, socio-economic status, family history of CVD, smoking, alcohol consumption, type 
1 and 2 diabetes mellitus, hypertension, obesity and disturbances of the plasma lipid profile. 
Some of these factors, such as age and gender are fixed and cannot be reversed; however 
other factors are adjustable and/or preventable. Intervention and improvements of these 
factors reduces the CVD burden. For example, healthy diet and physical activity reduce 
obesity, control blood pressure and improve the lipid profile; leading to a reduction of CVD 
risk. 39-40 
 
1.3.3  Plasma lipid profile 
Controlling the plasma concentration of lipoproteins is currently the most effective way of 
preventing CVD. Specifically, drugs aimed at reducing plasma LDL-C concentrations 
(Statins) have substantially reduced CVD deaths and prolonged lives. A lipid profile is 
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 considered atherogenic when one or several of the following measurements is observed; 
elevated total cholesterol (> 5.0 mmol/L), elevated LDL-cholesterol (>3.0 mmol/L), elevated 
TG (>2.0 mmol/L), and low concentration of HDL-C (<1.0 mmol/L). 41-46 
 
1.3.4 Plasma lipids and disease 
Therapies focusing on LDL-C reduction with statins have substantially reduced the CVD 
burden and saved many lives over the past four decades. However, the benefits of LDL-C 
lowering have shown to be not as efficient in patients suffering from extremely high LDL-C 
levels or other more complicated forms of dyslipidemias. There are also a substantial number 
of hypercholesterolemic patients experiencing adverse side effects from statins. Alternative 
LDL-C lowering therapies, such as PCSK9 inhibitors, are being clinically tested for these 
individuals. More recently, focus in treating abnormal lipid levels has broadened. Increasing 
number of patients suffering from Type 2 diabetes (T2D), obesity and insulin resistance are 
all characterized by elevated plasma TG levels reflecting in an increase concentration of 
remnant VLDL or CMs in the circulation. Patients with metabolic disorders such as insulin 
resistance are characterized by unbalanced FA turnover in the liver and in the adipose tissues. 
This causes an overproduction of larger VLDL particles leading to increased plasma TG 
levels, and low HDL levels and the generation of small, dense, CE-depleted LDL.45-55 
 
1.3.5 Intracellular lipids and disease 
The plasma TG concentration is closely linked to TG metabolism in the liver. Excessive 
accumulation of TGs in the liver leads to hepatic steatosis, a condition associated with 
adverse metabolic consequences, including insulin resistance and dyslipidemia, two 
important components of the metabolic syndrome. NAFLD is the most common form of 
hepatic steatosis in Western countries. This disease can develop from simple hepatic steatosis 
to irreversible cirrhosis.56-61 
 
1.4 GENOME WIDE ASSOCIATION (GWA) STUDIES  
 
A GWA study constitutes a biologically unbiased scanning of the genome of a population 
with the aims to find genomic loci that are associated with disease or intermediary 
phenotypes. It is an advanced form of linkage-mapping, a method developed to identify the 
cause of Mendelian disorders. To date, more than 2000 single nucleotide polymorphisms 
(SNPs) across all diseases have been discovered by GWA studies.61-65  
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1.5  MAPPING OF EXPRESSION QUANTITATIVE TRAIT LOCI  
 
Expression of quantitative trait loci (eQTL) mapping is a genomics approach to infer directly 
or indirectly the functional effect of genetic variants on gene expressions. Advances in 
technological platforms have allowed simultaneous mapping of the genome and the 
transcriptome in search for differences in genetic variation affecting gene expression. eQTL 
has been a crucial complement to quantitative trait locus (QTL) mapping, which is the 
mapping of genetic variation to a certain trait or phenotype. The ultimate goal of eQTL 
analyses is to find a genetic variation that either effects the expression of that particular gene 
(cis-eQTL) or the expression of a distant gene (trans-eQTL). eQTL analyses has also 
facilitated on understanding of the intricate relationship of gene networks with respect to 
causality to complex diseases.66-68 
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 2 AIMS 
 
The overarching aim of the thesis is to functionally characterize genes involved in the 
regulation of hepatic TG metabolism. 
 
The specific aims of these studies were:  
• To identify the genetic factors responsible for inter-individual differences of 
circulating plasma PCSK9 levels (paper I)  
• To uncover  the functional genetic variant(s) influencing the plasma APOE 
concentration (paper II) 
• To identify and functionally characterize the gene in the ‘NCAN region’ that is 
responsible for the association with plasma TG concentration and liver TG content 
(paper III) 
• To determine the role of PNPLA3 in the regulation of TG metabolism in human 
Huh7 hepatoma cells (paper IV) 
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3 MATERIAL AND METHODS 
 
3.1  STUDY COHORTS 
 
Biobanks and databases originating from 5 population-based studies of middle-aged 
subjects from the greater Stockholm area were used.  
• POLCA consists of 649 healthy 50-year-old men, free from CHD, who had been 
recruited at random using the population registry.  
• OLIVIA comprises 340 men and 340 women with a similar age distribution (33–80 
years), recruited according to the same principles for inclusion in the PROCARDIS 
program.  
• CORONA consists of 750 healthy men, free from CHD, aged between 40 and 65 
years (with 30 subjects for every age group), who had been recruited at random 
using the population registry.  
• 60YO is a population-based, cross-sectional cohort of a total of 4232 60-year-old 
men and women. Subjects on statin medication, with manifest diabetes mellitus, of 
non-European descent, or with incomplete genotype data were excluded from all 
analyses.  
Overall, a total of 624 subjects from POLCA, 591 subjects from OLIVIA, 719 
subjects from CORONA, and 3788 subjects from 60YO were evaluated. 
• ASAP is a cohort of 600 consecutive patients undergoing elective surgery due to 
aortic valve disease. Liver biopsy was taken from 210 of these subjects. 
These studies were performed with standardized protocols, approved by the Ethics 
Committee of the Karolinska Institute. All subjects were included after informed or signed 
consent.  
 
3.2  GENOTYPING  
 
Genotyping was performed using the Illumina (San Diego, CA) Infinium II Human 1M 
Beadchip for the OLIVIA cohort. The Illumina Infinium 610K quad Beadchip was used for 
the POLCA cohort. Illumina Human 610W-Quad Beadchip was used for the ASAP cohort 
at Uppsala University, Sweden.  
The GenomeStudio software from Illumina was used for genotype calling and quality 
control.  
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 Imputation was carried out on the quality-controlled genotypes of the combined POLCA-
OLIVIA data set. 
All Taqman genotyping assays were conducted in 384-well format, measured in the 
7900HT fast real-time polymerase chain reaction system (Applied Biosystems), and 
analyzed with the auto-analysis program.  
 
3.3  GENE EXPRESSION AND eQTL ANALYSIS 
 
Gene expression was analyzed in all liver samples using the Affymetrix GeneChip Human 
exon 1.0 ST array (Affymetrix, Santa Clara, CA). Blood was collected from all patients and 
genotyping was performed using Taqman assays (Applied Biosystems, Life Technologies, 
Carlsbad, CA). Standard plasma lipid analysis was performed with automated commercial 
assays. All protocols were approved by the ethics committee of the Karolinska Institutet 
and all subjects signed an informed and written consent.  
 
3.4  CELL CULTURE CONDITIONS AND TRANSFECTION STUDIES 
 
Human hepatoma HepG2 and Huh7 cells were obtained from the American Type Culture 
Collection (HB-8065; Manassas, VA) and the Health Science Research Resources Bank 
(cell no. JCRB0403; Osaka, Japan), respectively. Cells were grown in Dulbecco's Modified 
Eagle's Medium (Gibco, Life Technologies, Carlsbad, CA) supplemented with 10% fetal 
bovine serum, 50 U/mL penicillin, and 50 µg/mL streptomycin. Lipofectamine 2000 
(Invitrogen, Life Technologies, Carlsbad, CA) was used as transfection reagent. siRNA 
oligonucleotides were purchased from Ambion (Life Technologies, Carlsbad, CA). 
TransIT®-2020 Transfection Reagent (Mirus Bio LLC, Madison, WI) was used as 
transfection reagent for the overexpression studies. C-terminal GFP-tagged or FP635-
tagged full-length human TM6SF2 and CALR probes were obtained from OriGene 
(Rockville, MD).       
 
3.5  CELL FIXATION AND STAINING 
 
HepG2 and Huh7 cells were cultured in 4-well chamber slides. Fixation was performed 
with 3% Paraformaldehyde. All washing steps were performed with room temperature PBS.  
• For the antibody staining, cells were permeabilized for 45 minutes. Primary staining 
was performed with PDI, ERGIC53 or GIANTIN mouse monoclonal antibodies 
12 
 
 
 
(Enzo Life Sciences, Farmingdale, NY). Secondary staining was performed with 
goat anti-mouse Alexa Fluor 488 secondary antibody (Invitrogen, Life 
Technologies, Carlsbad, CA).  
• For the lipid-droplet analysis, cells were stained with 4,4-difluoro-1,3,5,7,8-
pentamethyl-4-bora-3a,4a-diaza-s-indacene (BODIPY493/503, Molecular Probes, 
Life Technologies, Carlsbad, CA). 
All cells were mounted with Vectashield mounting medium containing DAPI (Vector 
Laboratories, Burlingame, CA).  
 
3.6  CONFOCAL MICROSCOPY  
 
Images were obtained using a Leica SP5 confocal microscope, equipped with a 63×1.4 lens 
and diode and argon lasers. All images were generated using ImageJ software 
(http://rsb.info.nih.gov/ij/). Lipid-droplet area was quantified in each chamber slide using 
the Particle analysis Plugin of the ImageJ software. The number and area of the cells in 
each field were determined using the ImageJ cell-counter and particle analysis Plugin.  
 
3.7  BIOCHEMICAL ASSAYS 
 
Venous blood samples were obtained after an overnight fast. Plasma and serum intended for 
the biobank were aliquoted and stored at −70°C until analysis.  
Standard lipid analyses were performed with automated commercial assays, and APOB was 
determined by an immunoturbidometric assay.  
Plasma insulin concentration was measured by ELISA based on a monoclonal antibody 
(DAKO Ltd for POLCA and DakoCytomation Ltd for OLIVIA, Dako, Ely, 
Cambridgeshire, UK).  
Plasma concentrations of C-reactive protein (high-sensitivity range) and fibrinogen were 
determined by immunoturbidometric assays in the BN system (Dade Behring, Liederbach, 
Germany).  
Serum PCSK9 concentration was determined as described by Alborn et al.13 
The TM6SF2 antibody used in the Western blot experiments was purchased from Abnova 
(Heidelberg, Germany). Gene expression in the cell-culture experiments was quantified by 
real-time quantitative PCR using Taqman assays (Applied Biosystems, Life Technologies, 
Carlsbad, CA); RPLP0 was used as standard.  
TG secretion was quantified following 24 hour incubation of cells with 14C glycerol 
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 (PerkinElmer, Waltham, MA) at a final concentration of 2.85 mCi/mL. Lipids were phase 
separated by hydrophobicity phase separation and the upper lipophilic layer containing the 
TGs was separated using thin layer chromatography.  
The APOB in the cell-culture medium was quantified by ELISA (ALerCHEK, Springvale, 
ME).  
Cellular TG and protein concentrations were measured with assays supplied by Biovision 
(Milpitas, CA) and Thermo Fisher Scientific (Waltham, MA).  
 
3.8  STATISTICAL ANALYSIS 
 
The distribution of continuous variables in groups is expressed as mean ± SD or ± SEM.  
Differences in continuous variables between groups were tested by Student´s t test.  
The transcript units and the plasma triglyceride levels were logarithmically transformed for 
all other statistical analysis.  
Multiple linear regression was used to test the association between mRNA expression and 
the SNP coded by the number of major alleles, while ANOVA analysis was used to test the 
association between mRNA expression and the SNP genotypes.   
The Rcoloc values in the colocalization studies were calculated using the colocalization 
Plugin of the ImageJ software.      
Statistical analysis was performed in GraphPad Prism, PLINK and STATISTICA 
(STATsoft, Tulsa, OK). Calculation of linkage disequilibrium and identification of regions 
with high linkage disequilibrium were performed in Haploview 4.2. 
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4 RESULTS AND DISCUSSION 
 
4.1 COMMON AND LOW-FREQUENCY GENETIC VARIANTS IN THE PCSK9 
LOCUS INFLUENCE CIRCULATING PCSK9 LEVELS 
  
4.1.1  Aim 
Several studies have shown that circulating PCSK9 levels exhibit up to 50-fold variation in 
healthy, middle-aged subjects. It is therefore generally assumed that genetic components play 
an important role in the inter-individual variation in circulating PCSK9 levels. However, only 
one common genetic variant with a marked effect on circulating PCSK9 levels has thus far 
been identified, the rs11591147 SNP resulting in the PCSK9-R46L variant. The minor allele 
of rs11591147 has a frequency of only 1-2% in healthy Caucasians and is associated with a 
marked reduction in plasma LDL-C concentration. However, the rs11591147 SNP explains 
less than 1% of the overall variation in circulating PCSK9 level, suggesting that there are 
additional genetic variants influencing circulating PCSK9. Here, we used the GWA study 
approach to identify novel genetic variants contributing to the variation in plasma PCSK9 
levels and correspondingly LDL-C concentrations 71-73,76,80. 
 
4.1.2  Results 
We performed a GWA study using a discovery cohort of 1215 subjects and a replication 
cohort of 4507 subjects. All cohorts were composed of healthy, middle-aged subjects and 
none of the subjects were using lipid-lowering medication. In line with previous reported 
studies, a 50-fold variation of circulating PCSK9 levels was observed in all cohorts. 
Moreover, consistent positive relationships between the circulating PCSK9 levels and the 
plasma LDL-C and TG concentrations were observed. However, no SNPs were identified 
in the GWA study that showed a genome-wide statistical significant relationship with 
circulating PCSK9 level. Further analysis for the PCSK9-R46L variant in the discovery and 
replication cohorts demonstrated that the minor allele of the rs11591147 SNP is indeed 
associated with markedly reduced plasma PCSK9 levels and correspondingly LDL-C 
concentration. We decided therefore to focus on the PCSK9 locus and search in this 
genomic region for additional, independent SNPs associated with circulating PCSK9 levels.  
Dense SNP mapping of the PCSK9 locus was performed in the 1215 subjects from the 
discovery cohort. This resulted in the identification of 8 SNPs associated to circulating 
PCSK9 levels. Subsequent genotyping of the replication cohort identified 2 SNPs with 
genome-wide statistical significant relationships with the circulating PCSK9 levels: the 
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 previously reported rs11591147 (PCSK9-R46L) with a MAF 0.02 and a common 
polymorphism rs2479415 with MAF 0.44. The two SNPs were independently related to 
circulation PCSK9 levels. However, rs11591147 showed a strong relationship with the 
plasma LDL-C concentration, while only a weak relationship between rs2479415 and the 
plasma LDL-C concentration was observed.  
 
 
As shown in Figure 4, the position of rs2479415 SNP is 6kb upstream of the PCSK9 
transcriptional start site. This encouraged us to analyze the relationship between rs2479415 
and hepatic PCSK9 mRNA levels. As shown in Figure 5, a graded relationship between the 
rs2479415 genotypes and PCSK9 mRNA levels was observed. In contrast, no association was 
observed between rs11591147 and hepatic PCSK9 mRNA levels. 
 
4.1.3  Discussion 
In this study we identified the rs2479415 SNP in the PCSK9 promoter associated with 
circulating PCSK9 levels. This relationship is independent from the association between the 
rs11591147 SNP and circulating PCSK9 levels. Indeed, the minor allele of the rs2479415 
SNP is associated with increased PCSK9 levels, while the minor allele of the rs11591147 
Figure 5. Relationship between 
rs247915 genotype and statin-adjusted 
PCSK9 mRNA levels in 199 liver 
samples. P-values are from Student’s t 
test.   
Figure 4.  A) PCSK9 gene structure. B) 
Linkage-disequilibrium plot of SNPs in 
the PCSK9 gene locus from 1215 
subjects. Colors and values reflect R2 
measures of linkage disequilibrium. 
Arrows indicate the positions of the 
rs2479415 and rs11591147 SNPs. 
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SNP is associated with decreased PCSK9 levels. Moreover, a relationship between the 
minor allele of the rs2479415 SNP and the PCSK9 mRNA concentration was observed, 
while no relationship between the rs11591147 SNP and PCSK9 mRNA levels were found. 
It is therefore tempting to speculate that the rs2479415 SNP in the PCSK9 promoter 
influences the rate of transcription of PCSK9, ultimately leading to differences in 
circulating PCSK9 levels. Although the current data is in agreement with this hypothesis, 
there remain a number of unresolved questions. For example, our fine-mapping analysis is 
by current standards not really comprehensive. Indeed, a systematic analysis of all SNPs 
with a MAF>1% in a larger region around the PCSK9 gene in a considerably larger 
population is required to identify all SNPs with an association with circulating PCSK9 
levels independent from the PCSK9-R46L mutation. This type of comprehensive fine-
mapping is currently feasible and should lead to the identification of one or more additional 
SNPs with independent relationships to circulating PCSK9 levels. Indeed, we refrained 
from further functional analysis, as described for example for the SNP in the APOE 
promoter in Study II, while we were not certain that the rs2479415 SNP is indeed the ‘top’ 
SNP associated with circulating PCSK9 levels. 
The GWA study performed in this study did not lead to the identification of a new genetic 
locus related to circulating PCSK9 levels. Nevertheless, the same discovery cohort 
identified a robust genetic locus associated with the plasma APOE concentration (see Study 
II). This underlines some of the difficulties and uncertainties with the use of the GWA 
study approach for the identification of genetic loci for quantitative phenotypes. It is 
important that there is sufficient genetic contribution to the variation of the phenotype 
analyzed in the GWA study. As will be reported elsewhere, we found - using a classical 
twin-study design - that genetic factors accounted for ~36% of the variation in circulating 
PCSK9 levels. Another factor that may influence the success of the GWA study is the 
genetic coverage of the genome by the SNP array. In general, commercially available 
arrays are designed to capture the relationships between phenotype and common SNPs and 
are seldom able to identify relationships with SNPs with MAF <5%. An alternative 
approach to capture relatively rare SNPs in GWA studies is to evaluate the extremes of the 
distribution patterns of the phenotype, in this case subjects with very high or extremely low 
PCSK9 levels. However, it is generally agreed that an increase in the size of the study 
population, thereby increasing the power of the GWA study, is the single, most significant 
factor determining the success of the GWA study. By current standards, a discovery cohort 
of 1215 subjects in generally insufficient to identify novel genetic loci using the GWA 
study approach 71-81. 
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 4.2 IDENTIFICATION OF A FUNCTIONAL APOLIPOPROTEIN E PROMOTER 
POLYMORPHISM REGULATING PLASMA APOLIPOPROTEIN E 
CONCENTRATION. 
 
4.2.1  Aim 
APOE is a surface protein found on TRLs that act as a ligand for clearing of these 
lipoproteins from circulation through binding to LDLR. APOE has three known alleles ε2, ε3 
and ε4 coding for the APOE2, APOE3 and APOE4 isoproteins, respectively. The APOE 
isoproteins interact with different affinities with the LDLR. APOE2 has lower affinity for 
LDLR as compared to the common APOE3 isoprotein, while there is some evidence that 
APOE4 has a slightly higher affinity for LDLR as compared to APOE3. These differences in 
affinities for LDLR influence the rate of removal of remnant lipoproteins, but it is not clear if 
this phenomenon accounts for the whole spectrum of lipoprotein changes associated with the 
APOE locus.   
The association between the APOE isoforms and the plasma lipoprotein levels has been 
studied in considerable detail and it appears that the APOE isoforms are related to changes in 
the plasma cholesterol, TG, as well as APOE concentrations. It is generally assumed that the 
APOE isoforms are the primary genetic and functional determinants of the observed 
relationships with plasma LDL-C concentration Nevertheless, it remains uncertain if there are 
other genetics variants in the APOE locus that contribute to the regulation of the plasma 
lipoprotein levels, specifically in relation to the plasma TG and APOE concentrations. Here, 
we analyzed the impact of genetic variants in the APOE locus on the plasma APOE 
concentration.82-87 
 
4.2.2  Results 
We performed a GWA study of the plasma APOE concentration in 1766 subjects (Figure 6). 
A highly significant relationship was observed between the APOE locus and the plasma 
APOE concentration. However, no additional genetic loci with a relationship to the plasma 
APOE concentration were found. We therefore decided to concentrate on a further 
exploration of the APOE locus in an extended cohort of 2687 subjects. Using a dense map of 
SNPs in the APOE locus we identified four SNPs with a significantly association to plasma 
APOE concentration. The rs769446 SNP, located in the proximal promoter of APOE, was 
the only SNP that was independently associated to plasma APOE concentration, in addition 
the rs429358 and rs7412 SNPs which are the polymorphisms responsible for the APOE 
ε2/ε3/ε4 genotypes. 
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The relationship between rs769446 and the APOE mRNA expression was analyzed in 199 
liver samples. It was found that the minor allele of the rs769446 SNP was associated with 
increased hepatic APOE mRNA levels (Figure 7). Of note, the minor allele of the rs769446 
SNP was also associated with increased plasma APOE concentration, indicating that the 
rs769446 SNP in the APOE promoter influences the rate of transcription of APOE, ultimately 
leading to an increased plasma APOE concentration. Functional studies were performed in 
HepG2 cells to substantiate this hypothesis. As shown in Figure 7 the C-allele of the 
rs769446 SNP showed a higher basal rate of transcription as compared to the common T-
allele (Figure 7B). Electromobility shift assay analysis demonstrated quantitative differences 
in the binding of nuclear factor(s) to the different alleles of the rs769446 SNP. Overall, these 
observations are compatible with the notion that the rs769446 SNP influences the binding of 
nuclear factor(s) to the APOE promoter, thereby influencing the rate of transcription of 
APOE, ultimately leading to an increased plasma APOE concentration of carriers of the 
minor allele of the rs769446 SNP.   
 
 
Figure 6. Manhattan plot.  P values for association 
with plasma apolipoprotein E (APOE) 
concentration.  rs769446, rs405509, rs429358, and 
rs7412 shown in red achieved genome-wide 
significance. 
 
Figure 7. A) Graded association between rs769446 and 
plasma APOE levels in 199 subjects. Increased basal 
transcription rate of the rs769446-C allele as compared 
with the rs769446-T allele shown in B, and by 
electrophoretic mobility shift assay showing a distinct 
difference in binding of nuclear factors between 30-bp 
fragments containing either the rs769446-C site or the 
rs769446-T site. D) Quantitative analysis of protein–
DNA complex indicated with arrow in C 
demonstrating significant differences between the 
rs769446-C and the rs769446-T fragments. 
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 The availability of a SNP with a relationship to the APOE concentration independent from 
the APOE genotype creates the opportunity to test the effect of APOE concentration on 
plasma lipoprotein levels. To this end we analyzed the relationships between the rs769446 
and plasma lipoprotein concentrations in subjects with the APOE ε3/ε3 genotype, thereby 
excluding the effects of the APOE genotype on lipoprotein levels. As shown in Table 1, no 
evidence was found for an association between the rs769446 genotype and plasma lipoprotein 
concentrations.  
 
Table 1. Associations between rs769446 genotype and the plasma lipoprotein concentrations in subjects with 
the APOE ε3/ε3 genotype. 
 
 
4.2.3  Discussion 
In this study we identified and functionally characterized the rs769446 SNP in the APOE 
promoter. An important characteristic of this SNP is the associated to the plasma APOE 
concentration. This relationship is independent from the APOE genotype. This feature of the 
rs769446 SNP makes it possible to evaluate the association between the plasma APOE 
concentration and the plasma lipoprotein concentrations. We performed this analysis in two 
large cohorts of subjects with the APOE ε3/ε3 genotype, thereby excluding the impact of the 
APOE genotype on lipoprotein levels. However, no evidence was found for an effect of the 
rs769446 SNP on plasma lipoprotein concentrations, suggesting that variation of the plasma 
APOE concentration has no effect on the plasma concentrations of the major lipoprotein 
classes. This observation is surprising, while it was generally assumed that the APOE 
concentration, in addition to the APOE genotype, was a determinant of plasma lipoprotein 
concentrations. Indeed, case-control studies had suggested that the plasma APOE 
concentration influences the risk for CHD, presumably as a consequence of the effect of the 
APOE level on plasma lipoprotein concentration. However, the absence of an effect of 
genetic variation of the plasma APOE concentration on the plasma lipoprotein levels, as 
reported in this study, makes it unlikely that the APOE concentration influences the risk of 
CHD. Nevertheless, this conclusion remains to be tested experimentally. 
It has generally been assumed that the APOE genotype is exclusively responsible for the 
relationships between the APOE locus and the plasma lipoprotein concentrations. The 
identification of the rs769446 SNP in the APOE promoter as a functional SNP with an 
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independent relationship with the plasma APOE concentration thus provides evidence for a 
role of addition SNPs in the APOE locus in the regulation of plasma lipoprotein 
concentrations. As outlined above, there is evidence that the APOE genotype plays a major 
role in the regulation of the plasma LDL-C concentration. However, there is no convincing 
experimental data substantiating a role of the APOE genotype in the regulation of the plasma 
TG concentration. Indeed, the APOE gene is located in close proximity to APOC1, a member 
of the APOC-family with roles in the metabolism of TRLs. This raises the possibility that 
other SNPs in the APOE locus effect the metabolic function of APOC1, thereby influencing 
the plasma TG concentration independent from the APOE genotype. This hypothesis can be 
tested experimentally by performing a fine-mapping analysis of the APOE locus in a large 
cohort of healthy subjects and evaluating the relationship with plasma TG concentration. 82-87 
 
4.3 TM6SF2 IS A REGULATOR OF LIVER FAT METABOLISM INFLUENCING 
TRIGLYCERIDE SECRETION AND HEPATIC LIPID DROPLET CONTENT. 
 
4.3.1 Aim 
Several GWA studies have identified a locus on chromosome 19p12, sometimes termed 
NCAN locus, associated with the plasma TG and LDL-C concentrations. More recently, the 
same genetic locus was found to be associated with hepatic lipid content in healthy human 
subjects. However, at least 19 different genes are present in the chromosome 19p12 locus and 
the gene responsible for the reported associations has not been identified. The aim of this 
study was to identify the causal gene and to characterize the functional role of this gene in TG 
metabolism.88-89 
 
4.3.2 Results 
When performing genome wide expression analysis in relation to different plasma lipid levels 
in 206 liver samples, we observed a strong correlation between TM6SF2, a gene with then 
unknown function, and circulating TGs levels (Figure 8). This gene was located on the 19p12 
locus, which was previously shown to being associated to hepatic and plasma TG levels. The 
lead SNP in these reports was the rs10401969. We observed that the carriers of the minor 
rs10401969 allele had lower TM6SF2 mRNA levels, indicating a role of the polymorphism 
on both mRNA levels and circulating TGs. We also observed, in accordance with recent 
observations, that TM6SF2 was expressed in the liver and the small intestine; organs of 
importance regarding synthesis and secretion of TRLs.   
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Nothing about TM6SF2 other than its sequence homology to TM6SF1 was known to that 
date. The nomenclature suggested it to be a transmembrane protein. Analysis of the sequence 
in ProtScale and other alignment tools showed 7-10 transmembrane rigions within the gene. 
To localize TM6SF2 we transfected Huh7 cellls with GFP tagged plasmids and observed the 
protein to be expressed in the ER (Figure 9). 
Figure.8  A) Hepatic mRNA levels of the 19 
genes in the 19p12 locus. B) –Log10p-value 
plot of rs10401969 association to the mRNA 
levels of the 19 genes in the 19p12 locus. C) 
Association of the rs10401969 genotypes to 
hepatic TM6SF2 mRNA levels. D) Hepatic 
TM6SF2 mRNA correlation to plasma TG 
levels. E) –Log10p-value plot of mRNA 
levels of all the genes in the 19p12 locus to 
plasma TG levels. F) –Log10p-value plot of 
mRNA levels of all the genes in the 19p12 
locus to plasma cholesterol levels 
22 
 
 
 
 
Figure 9. A) Localization of TM6SF2-GFP (green) and CALR-FP635 (red) proteins in Huh7 cells. B) 
Localization of TM6SF2-GFP (green) with Alexa633-tagged PDI, ERGIC53 and GIANTIN antibodies in Huh7 
cells. 
 
To characterize the functionality of the TM6SF2, we performed a series of transient 
transfection experiments in Huh7 and HepG2 cells using TM6SF2 siRNA and TM6SF2-
tagged plasmids. We observed an increase in intracellular TGs and a reduction of secreted 
TGs when silencing the TM6SF2 (Figure 10). 
 
 
 
Figure 10. Accumulation of TGs in Huh7 cells after TM6SF2 inhibition measured with a) biochemical assay and 
B) confocal microscopy (green represents TG staining).  
 
Interestingly, TM6SF2 siRNA reduced the expression of secreted APOB100 also and showed 
to reduce the expression of genes involved in TG synthesis (Figure 11).  
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Reversely, we observed increased accumulation of TGs in cells overexpressing the TM6SF2 
protein. We could not measure the secreted TRLs in the overexpressed experiments probably 
due to a low net effect of the expressed TM6SF2 protein on in-vitro TG levels (Figure 12).  
 
 
Figure 12. Huh7 cells transfected with TM6SF2-FP635 (above red) or CALR-FP635 (below red). Green 
represents TGs in LDs. Higher TG accumulation observed in cells overexpressing the TM6SF2 protein 
compared to the cells not overexpressing TM6SF2. 
 
4.3.3  Discussion 
We found that this protein was an ER membrane protein with 7-10 trans-membrane regions. 
In Huh7 and HepG2 cells, the inhibition of TM6SF2 showed dual functionality; we observed 
increased hepatic TG levels as well as LD size and content reducing secreted TGs. Reversely, 
the increased expression of the protein had opposing intracellular effects to inhibition; LD 
content was reduced in cells overexpressing the TM6SF2 protein.  
Figure 11. A & C) Western blot analysis in Huh7 and HepG2 cells 
48-hours post TM6SF2 inhibition. B & D) Protein quantification of 
the western blot bands in A & C. E) Expression of genes involved in 
hepatic lipid metabolism 48-hours post TM6SF2 inhibition F) 
Secreted TG and APOB levels 48-hours post TM6SF2 inhibition in 
Huh7 and HepG2 cells. 
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Recently, two other studies reported similar results in mice models. Knockdown of Tm6sf2 
or transient TM6SF2 overexpression in mice alters serum lipid profiles and influences 
hepatic TG content. However the functional role of TM6SF2 in regulating intracellular and 
secreted TG levels remains unclear.  
TM6SF2 is solely expressed in the intestine and the liver in humans, organs of importance 
regarding TRL secretion. Inhibition of the protein although having reduced effects on both 
secreted TG and APOB levels, the magnitude of this reduction varies, therefore suggesting 
less incorporation of TGs in VLDL particles. TM6SF2 inhibition also reduces the 
expression of TG synthesis genes. We therefore conclude that TM6SF2 probably primarily 
affects VLDL synthesis and secondarily affects TG accumulation and LD formation. Our 
views slightly deviate from the conclusions of the other groups who believe TM6SF2 is 
involved in the regulation of VLDL secretion and not synthesis. However, all of these 
groups accept the impairment of the expression of the gene to causing intracellular TG 
accumulation.88-93 
 
4.4 ROLE OF PATATIN-LIKE PHOSPHOLIPASE DOMAIN-CONTAINING 
PROTEIN 3 (PNPLA3) IN THE REGULATION OF TRIGLYCERIDE 
METABOLISM IN HUMAN HUH7 HEPATOMA CELLS 
 
4.4.1 Aim 
The PNPLA3 gene variant I148M is an important marker of human non-alcoholic fatty liver 
disease (NAFLD), but the physiological function of PNPLA3 in liver fat metabolism 
remains unclear. Indeed, mouse Pnpla3 knockout models showed no phenotype under a 
variety of dietary conditions. Specifically, no evidence was found for hepatic steatosis in 
Role of patatin-like phospholipase domain-containing protein 3 the Pnpla3 knockout mice. 
These observations suggest that PNPLA3 plays no significant physiological role in TG 
metabolism in mice, but it remains possible that PNPLA3 contributes to hepatic TG 
metabolism in man. Here, we analyzed PNPLA mRNA levels in human and mouse tissues 
and evaluated the effect of small interfering RNA (siRNA) silencing of PNPLA3 on 
triglyceride metabolism in human Huh7 and HepG2 hepatoma cells in an effort to elucidate 
a possible role of PNPLA3 in hepatic TG metabolism.94-99 
 
4.4.2  Results 
The hepatic expressions of the PNPLA3, PNPLA2 and PNPLA4 genes were compared in 
human and mouse liver samples and in the human hepatoma Huh7 cell-line. It was found that 
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 PNPLA2 was prominently expressed in mouse liver, while PNPLA3 was the highest 
expressed member of the PNPLA-family in human liver and the human hepatoma Huh7 cell-
line. These species specific differences in hepatic expression of PNPLA-family members 
suggest that it is feasible that human PNPLA3, in contrast to mouse PNPLA3, plays a 
significant role in hepatic TG metabolism.  
In analogy to the physiological role of PNPLA2 in TG-hydrolysis in WAT it can be expected 
that the putative role of PNPLA3 in hepatic TG-metabolism is related to the TG-hydrolysis 
activity of PNPLA3. This in turn suggests that PNPLA3 resides in hepatocytes in a 
subcellular compartment in the vicinity of LDs. It was indeed reported that PNPLA3 was 
observed near LDs following oleate treatment, while under unstimulated conditions PNPLA3 
showed a ubiquitous distribution. We therefore tested this phenomenon in Huh7 cells using 
confocal microscopy. As shown in Figure 15, (extreme) overexpression of PNPLA3 leads to 
ubiquitous expression of the protein in the cytoplasm. However, when PNPLA3 is 
moderately expressed it is localized around LDs. Of note, these studies were performed in the 
absence of oleate-treatment, indicating that oleate-treatment is not an obligatory requirement 
for localization of PNPLA3 around LDs.  
In order to study the functional role of PNPLA3 we reduced the expression of PNPLA3 in 
Huh7 and HepG2 cells using siRNA inhibition and evaluated the effects on TRL secretion 
and cellular TG content. However, no effects on TRL secretion were observed and no 
significant changes in cellular TG content were found. Confocal microscopy analyses were 
performed to validate these observations. As shown in Figure 13, PNPLA3 siRNA inhibition 
had no effect on the LD content or size distribution in Huh7 cells, and similar results were 
obtained in HepG2 cells.  
 
Figure 13. A) Confocal image of control and PNPAL3 siRNA cells showing no visual difference in the 
amount of LD (in green), which is expressed in B as LD area per cell. There was no difference in the size 
distribution of the LD particles measured in C. Same experiment was conducted in HepG2 cells with similar 
results. 
 
We considered the possibility that PNPLA3 influences TG synthesis, not TG hydrolysis as 
would be expected by comparison with the physiological role of PNPLA2 in white adipose 
tissue. However, as shown in Figure 14, PNPLA3 siRNA inhibition had no effect on the 
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cellular uptake of [14C]palmitate or the incorporation of [14C]palmitate into triglycerides in 
Huh7 cells, and the same phenomenon was observed in HepG2 cells. 
 
 
Figure 14. Total cellular [14C]-radioactivity, representing palmitate uptake (A), and triglyceride associated 
[14C]-radioactivity, representing triglyceride synthesis (B) at 4 time-points. Red line represents the PNPLA3 
siRNA samples while the black is the control siRNA. 
 
 
4.4.3  Discussion  
In this study we evaluated the putative role of PNPLA3 in hepatic TG metabolism in human 
liver and human hepatoma cells. Several lines of evidence pointed to a physiological role of 
PNPLA3 in hepatic TG metabolism, including a high expression level of PNPLA3 in human 
liver and a subcellular localization of PNPLA3 around the LDs in Huh7 cells. However, 
experimental reductions in PNPLA3 concentrations in human hepatoma cells were not 
associated with significant changes in the secretion of TRL, with increased cellular 
accumulation of TGs, or with changes in the rate of TG synthesis. These observations thus 
provide further evidence against a major physiological role of PNPLA3 in hepatic TG 
metabolism in man. This provides further support for the hypothesis proposed by Hobbs and 
coworkers that the PNPLA3 variant I148M represents a gain-of-function mutation leading to 
excessive accumulation of TGs in the liver in man. 
The observed absence of a physiological function of PNPLA3 in hepatic TG metabolism 
raises the question of the nature of the enzyme responsible for TG-hydrolase activity in 
human liver. It was recently reported that PNPLA2 is the primary enzyme responsible for 
TG-hydrolase activity in the mouse liver. It is therefore tempting to speculate that PNPLA2 
fulfills a similar role in human liver. However, preliminary experiments from our laboratory 
found no evidence for a significant contribution of PNPLA2 to hepatic TG-hydrolase activity. 
Figure 15. Representative picture of A) PNPLA3-
FP635 expression (red), LDs in green. The two 
Arrows indicate overexpression of PNPLA3. B) 
magnification of the box in A. Moderate expression 
of PNPLA3 (red) at the vicinity of the LDs (green). 
Experiment performed in Huh7 cells. 
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 This suggests that an as yet unidentified gene/protein is responsible for TG-hydrolase activity 
in human hepatocytes. We are currently exploring if other members of the PNPLA-family are 
involved in this process.100 
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5 CONCLUDING REMARKS 
 
Understanding the pathophysiology of complex diseases is challenging. Unlike monogenic 
diseases, complex diseases do not follow a linear pattern of inheritance and are caused by 
multiple genes and their interplay with other genetic, environmental and behavioral factors. 
Recent GWA studies have uncovered thousands of SNPs associated with complex diseases 
and intermediary phenotypes. Nevertheless, these SNPs explain thus far only a minor fraction 
of the total disease-risk or the overall variation in intermediary phenotype. Moreover, the 
identification of these SNPs only constitutes a first step to uncovering underlying genes and 
pathways responsible for the observed associations between genotype and disease. In this 
thesis, I presented studies related to four proteins involved in lipid metabolism, PCSK9, 
APOE, TM6SF2 and PNPLA3. The results of these studies will help to improve our 
understanding of the physiological roles of these proteins in hepatic metabolism. At the same 
time, these studies represent only a small step towards the ultimate goal to provide 
personalized forms of therapy tailor-made according to the individual’s genetic variation.  
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